Logo

Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

Share this
Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

Shots:

  • The company initiates the P-IIa (PREVAIL-2) POC study to evaluate the efficacy & safety of PRV-3279 (q4w for 5mos.) vs PBO in ~100 patients with SLE across ~28 sites in the US & Hong Kong. The results are expected in 2024
  • The 1EPs is to evaluate the ability of PRV-3279 to reduce SLE flare. The therapy was well-tolerated in a prior SAD in P-I study & MAD in P-Ib (PREVAIL-1) study, reduction in IgM production @8wks.
  • The company collaborated with Hangzhou Zhongmei Huadong to develop & commercialize PRV-3279 in Greater China. PRV-3279 is a humanized bispecific DART molecule targeting CD32B & CD79B & has the potential to intercept the pathophysiology of SLE & B cell-mediated autoimmune diseases

Ref: PR Newswire | Image: Provention Bio

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions